- βParticipants lost an average of 11.5 kg (25 lbs) over 24 weeks
- β72% of participants were able to stop short-acting insulin entirely
- βBlood sugar (HbA1c) improved significantly among program completers
- β88% enrollment and 71% completion rates show the program is practical and well-received
- βVirtual visits made the program accessible without requiring in-person travel
| Journal | JMIR diabetes |
| Year | 2025 |
| PMID | 41397294 |
What Was This Study About?
Researchers at the Veterans Health Administration (VA) tested a 24-week program combining low-carbohydrate (low-carb) diet counseling with continuous glucose monitoring (CGM) for Veterans with type 2 diabetes who were on insulin. The goal was to see if this approach was safe, practical, and effective.
Who Was Involved?
38 Veterans with type 2 diabetes enrolled in the program. Most were men (97%), with an average age of 64 years. All participants were taking at least 3 daily insulin injections when they started.
How Did the Program Work?
Over 24 weeks, participants had virtual appointments with a registered dietitian (RD) and a clinical pharmacy practitioner (CPP). CGM data was used to personalize nutrition advice and safely adjust or stop diabetes medications as blood sugar improved.
Key Results
- Weight loss: On average, participants lost 11.5 kg (about 25 lbs), equal to roughly 9.5% of their body weight.
- Insulin reduction: 72% of participants were able to stop their short-acting insulin, and 50% stopped their long-acting insulin entirely.
- Blood sugar improvement: Among those who completed the program, HbA1c (a 3-month blood sugar average) dropped by 0.7%.
- Program completion: 71% of enrollees finished the full 24-week program, showing strong acceptability.
Why Does This Matter for Patients?
Many people with type 2 diabetes worry that cutting carbs while on insulin could be dangerous. This study shows that with proper monitoring and professional support, a low-carb approach can be done safely β and may significantly reduce the need for insulin injections, which can improve quality of life and lower medication costs.
What Are the Limitations?
This was a small pilot study without a control group, so results should be interpreted carefully. Longer, larger studies are needed to confirm these benefits and assess cost-effectiveness over time.
